Alterity Therapeutics presented data from its Phase 2 clinical trial in Multiple System Atrophy (MSA) at the American Neurological Association meeting. The trial showed that ATH434 slowed disease progression and reduced iron accumulation in MSA affected brain regions at 50 and 75 mg doses. The drug also demonstrated clinically meaningful efficacy and was well tolerated with no serious adverse events. Results indicate ATH434’s potential as a disease-modifying therapy for MSA.

The Phase 2 trial evaluated 77 adults with MSA who received ATH434 or placebo for 12 months. Participants taking ATH434 showed significant improvement on disability scales and motor performance compared to placebo. The drug also reduced iron accumulation in MSA affected brain regions and had a favorable safety profile. The study confirms ATH434’s potential as a promising treatment for MSA, a rare and rapidly progressive neurodegenerative disease.

Alterity Therapeutics is dedicated to developing disease modifying therapies for neurodegenerative diseases, with a focus on Parkinson’s disease and related disorders. Their lead candidate, ATH434, has shown positive results in Phase 2 trials for MSA. The drug has been granted Fast Track Designation by the FDA and Orphan Drug Designation by both the FDA and the European Commission for MSA treatment. Alterity’s research aims to create a better future for those living with neurodegenerative diseases.

Read more at GlobeNewswire: Alterity Therapeutics Presents ATH434-201 Phase 2 Data at